nutrition-health-gastroenterologists-2019-keynote

3 / 8

allied
academies
Page 14
Journal of Nutrition and Human Health | Volume 3
May 23-24, 2019 | Vienna, Austria
Joint Event
2nd International Conference on Gastroenterology and Digestive Disorders
17th International Conference on Nutrition and Fitness
&
D espite the fact that increasing amount of resources
is put into the treatment of pancreatic cancer, one
of the most aggressive and lethal forms of cancerous
diseases, the therapeutical outcome remains poor.
Chemotherapeutic agents such as Gemcitabine were
found to have a positive influence on the quality of life
in pancreatic cancer patients, however, median survival
times in patients treated with gemcitabine were only
marginally prolonged. Protocols using combinations of
gemcitabine with 5-fluoruacil with or without folinic
acid or combinations of gemcitabine and cisplatinium
have prolonged median survival, however these results
remain unsatisfactory. As such, finding a therapeutic
agent, that can further extend the median survival
as well as improve the quality of life of patients with
pancreatic cancer remains a top priority. In recent years
research with NSC631570 has shown promising results
in the treatment of unresectable pancreatic cancer with
actuarial survival rates of 86.7% after one year, 76.6%
after two years, 46.7% after three years and 23.3%
after five years and a median survival time according to
Kaplan-Meier regression analysis of 33.8 months. These
promising clinical results justified further research
on the exact mechanism of action as well as further
possible beneficial effects of NSC-631570.
Speaker Biography
Wassil Nowicky is the Director of Nowicky Pharma and President of
the Ukrainian Anti-Cancer Institute (Vienna, Austria). He finished his
study at the Radiotechnical Faculty of the Technical University of Lviv
(Ukraine) in 1955 with graduation to “Diplomingeniueur” in 1960
which title was nostrificated in Austria in 1975. He became the very
first scientist in the development of the anticancer protonic therapy
and is the Inventor of the preparation against cancer with a selective
effect on basis of celandine alkaloids “NSC-631570”. He used the
factor that cancer cells are more negative charged than normal cells
and invented the celandine alkaloid with a positive charge thanks to
which it accumulates in cancer cells very fast. He has been invited as
an Honorable Speaker in many scientific international congresses and
conferences in USA, Australia, Japan, UAE and Europe. He has over
300 scientific articles dedicated to cancer research. He is a Member
of the New York Academy of Sciences, European Union for Applied
Immunology and of the American Association for Scientific Progress,
Honorary Doctor of the Janka Kupala State University in Grodno, Doctor
“Honoris Causa” of the Open International University on Complex
Medicine in Colombo, Honorary Member of the Austrian Society of a
name od Albert Schweizer. He has received the award of merits from
National Guild of Pharmacists of America, the Award of Austrian Society
of Sanitary, Hygiene and Public Health Services and others.
e:
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
The effect of NSC631570 (Ukrain) on Pancreatic Cancer
Notes: